Cancer Forums and News by PhD's

News | Forums Register

Go Back   Cancer Forums and News by PhD's > Cancer Forums and News

Cancer News


Cancer Review


Recent Forum Topics

New lymphoma therapy may be more effective with fewer side effects
By Dross at 2010-11-04 22:51

Weill Cornell researchers report on targeted therapy to repress protein mutations in diffuse large B-cell lymphomas

NEW YORK (Nov. 3, 2010) -- Diffuse large B-cell lymphomaterm (DLBCL) is a type of aggressive non-Hodgkin's lymphoma that accounts for approximately 40 percent of lymphomas among adults. If left untreated, it is fatal. The existing treatments have a cure rate that is slightly over 50 percent but destroy healthy cells along with the cancer cells.

read more | 1640 reads

Study makes exciting progress in elucidating the mechanisms of bortezomib in lymphoma
By Dross at 2010-07-14 03:41

A new study by researchers from the John Theurer Cancer Center at Hackensack University Medical Center sheds light on how bortezomib (VELCADE®), the first in a new class of cancer drugs known as proteasome inhibitors, works in mantle cell lymphomaterm. The study also provides preliminary evidence for which patients might benefit most from bortezomib. Additionally, researchers demonstrate that biomarkers – the genes and proteins that indicate biological processes – might help guide the selection of patients for specific clinical trials and speed-up the development of targeted cancer drugs.

read more | 1352 reads

Yale study offers insight into possible cause of lymphoma
By Dross at 2008-02-15 05:11

The immune system's powerful cellular mutation and repair processes appear to offer important clues as to how lymphatic cancer develops, Yale School of Medicine researchers report this week in Nature.

"The implications of these findings are considerable," said David Schatz, a Howard Hughes Medical Institute investigator, professor of immunobiology at Yale, and senior author of the study. "It now seems likely that anything that compromises the function of these DNA repair processes could lead to widespread mutations and an increased risk of cancer."

read more | 1495 reads

Jefferson scientists studying the effects of high-dose vitamin C on non-Hodgkin lymphoma patients
By Dross at 2008-01-03 02:40

(PHILADELPHIA) - Scientists at Thomas Jefferson University Hospital and Jefferson’s Kimmel Cancer Center have received approval for a first-of-its kind study on the effect high dose vitamin C has on non-Hodgkin lymphomaterm patients. Researchers from the Jefferson-Myrna Brind Center of Integrative Medicine and Kimmel Cancer Center in conjunction with the National Institutes of Health will study whether high doses of vitamin C can slow the progression of the deadly disease.

“This is a very unique study for a set of patients who have really run out of options,” said Daniel Monti, M.D., director of the Myrna Brind Center of Integrative Medicine, and primary investigator of the study. “Vitamin C administered intravenously has shown great promise in the laboratory and there has been some anecdotal data in cancer patients, but no one has really ever run a detailed study on humans. Vitamin C doesn’t cost much and is very low in toxicity, making it a particularly desirable agent for further study.”

read more | 1666 reads

New Lymphoma treatment fights SYK causing cell death
By Dross at 2007-07-13 00:43

Doctors at the University of Rochester’s James P. Wilmot Cancer Center are first in the world to study a new, targeted agent that zeroes-in on B-cell lymphomas. The new twice-a-day pill offers patients with recurrent disease another choice as their options grow thin.

This investigative drug, R788, targets a common protein in normal B cells - white blood cells that fight infection -- and lymphomaterm cells. Previous studies have shown that inhibiting the activity of this protein, called SYK, spurs cellular death. 

Jonathan Friedberg, M.D., director of hematological malignancies clinical research, is studying this drug to determine its impact on stubborn lymphomas. “If our standard therapies aren’t working for these patients who see their remissions fail repeatedly, then this drug might work for them,” Friedberg said. He said that if there is widespread success, this drug, in combination with other therapies might be a good one-two punch for lymphoma.

read more | 3240 reads

Risk of lymphoma increases with hepatitis C virus infection
By Dross at 2007-05-10 01:55

People infected with the hepatitis C virus (HCV) are at an increased risk of developing certain lymphomas (cancers of the lymphatic system), according to a study published in the May 8, 2007, issue of the Journal of the American Medical Association. Researchers from the National Cancer Institute (NCI), part of the National Institutes of Health, and Baylor College of Medicine, found that HCV infection increased the risk of developing non-Hodgkin's lymphomaterm by 20 percent to 30 percent. The risk of developing Waldenström's macroglobulinemia (a rare type of non-Hodgkin's lymphoma) went up by 300 percent and the risk for cryoglobulinemia, a condition marked by abnormal levels of certain antibodies in the blood, was also elevated for those with HCV infections.

read more | 1795 reads

What You Need To Know About Non-Hodgkin's Lymphoma
By Dross at 2007-03-05 05:41

What Is Non-Hodgkin's Lymphomaterm?


Non-Hodgkin's lymphoma (also called NHL) is cancer that begins in the lymphatic system. To understand this disease, it is helpful to know about the lymphatic system.


The Lymphatic System


The lymphatic system is part of the body's immune system. The immune system fights infections and other diseases. In the lymphatic system, a network of lymph vessels carries clear fluid called lymph. Lymph vessels lead to small, round organs called lymph nodes. Lymph nodes are filled with lymphocytes (a type of white blood cell). The lymph nodes trap and remove bacteria or other harmful substances that may be in the lymph. Groups of lymph nodes are found in the neck, underarms, chest, abdomen, and groin. Other parts of the lymphatic system include the tonsils, spleen, and thymus. Lymphatic tissue is also found in other parts of the body including the stomach, skin, and small intestine. Lymphatic system. Lymphatic system. Non-Hodgkin's Lymphoma There are many types of non-Hodgkin's lymphoma. All types of lymphoma begin in cells of the lymphatic system. Normally, cells grow and divide to form new cells as the body needs them. When cells grow old, they die, and new cells take their place. Sometimes this process goes wrong. New cells form when the body does not need them, and old cells do not die when they should. These extra cells can form a mass of tissue called a growth or tumor. Non-Hodgkin's lymphoma begins when a lymphocyte (a B cell or T cell) becomes abnormal. Usually, non-Hodgkin's lymphoma starts in a B cell in a lymph node. The abnormal cell divides to make copies of itself. The new cells divide again and again, making more and more abnormal cells. The abnormal cells are cancer cells. They do not die when they should. They do not protect the body from infections or other diseases. Also, the cancer cells can spread to nearly any other part of the body.

read more | 3 comments | 26302 reads

Researchers Funded by The Leukemia & Lymphoma Society Studying Agent to Target Gene Linked to Many Forms of Lymphoma
By Dross at 2007-02-21 01:00

More than 60,000 Americans are living with lymphomaterm, and researchers have identified one gene in particular, BCL6, as playing a dominant role in causing many forms of this blood cancer. By determining which lymphomas are likely caused by this gene, a team of researchers from Albert Einstein College of Medicine in the Bronx, and Dana- Farber Cancer Institute in Boston, hope they will be able to identify which patients would be most responsive to a novel targeted treatment (BPI) which in lab tests has been found to inhibit BCL6 and kill lymphoma cells.


read more | 2033 reads

Lombardi expert helps set new guidelines for assessing lymphoma treatment
By Dross at 2007-02-07 05:02

    An international team of cancer specialists and imaging experts, including Bruce Cheson, professor of medicine, head of hematology, and director of hematology research at Georgetown's Lombardi Comprehensive Cancer Center, has developed standardized guidelines for assessing how lymphomas respond to treatment. The guidelines will provide clinicians worldwide with consistent criteria to compare and interpret clinical trials of lymphomaterm treatments and should facilitate the development of new therapies. The recommendations appear in the Jan. 22 online issue of the Journal of Clinical Oncology.

read more | 1952 reads

UCLA Researchers Discover Genes Linked to Lymphoma, Opening Way for New Targeted Drugs
By Dross at 2007-01-31 00:43


Lymphomaterm is a blood cancer that affects more than 60,000 Americans each year.


Researchers at The University of California Los Angeles have identified genes that when inactivated help cause B-cell non-Hodgkin's lymphoma (NHL).


These genetic defects may also be involved in promoting the formation of other cancers since they can inactivate normal tumor-suppressing gene activities in a range of cell types. The team led by Michael Teitell, M.D., Ph.D., and funded by The Leukemiaterm & Lymphoma Society, used genetically engineered mice to accurately mimic human B-cell cancers. They had previously published research in which they identified frequent genetic abnormalities in cancer cells from NHL patients -- namely defects in the TCL1 gene -- and showed that TCL1 abnormalities can cause NHL in mice when accompanied by additional genetic defects. Now, they have found some of these cancer collaborators. Teitell's team used a powerful genetic technique called "restriction landmark genomic scanning" (RLGS) to find genes that work with abnormal TCL1 to promote lymphoma formation.

read more | 3792 reads

FDA Approves VELCADE(R) (Bortezomib) for Injection for Aggressive Form of Non-Hodgkin's Lymphoma
By admin at 2006-12-09 05:48

Millennium Pharmaceuticals, Inc. (NASDAQ:MLNM) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval of VELCADE for the treatment of patients with mantle cell lymphomaterm (MCL) who have received at least one prior therapy. MCL is a relatively uncommon and aggressive form of non-Hodgkin's lymphoma for which there was no standard of care in the relapsed or refractory setting. MCL has a U.S. prevalence of 10,000 patients. VELCADE is currently the market leader in multiple myeloma (MM) for patients who have received one prior therapy. Today's approval marks the first indication for VELCADE in lymphoma, the most common blood cancer.

read more | 1674 reads

Familial (inherited) leukemia, lymphoma, and myeloma: an overview.
By admin at 2006-11-22 11:03

* Segel GB, * Lichtman MA. Department of Pediatrics, University of Rochester Medical Center, Rochester, NY 14642, USA.


We have reviewed the world's literature that addresses familial leukemiaterm, lymphomaterm, and myeloma. We have catalogued the phenotypic abnormalities associated with an increased risk of developing a hematological malignancy. These syndromes, such as Fanconi anemia or familial platelet syndrome, have been well characterized and in many cases the gene responsible for the predisposition has been defined. We have focused, however, on reports of a familial incidence of hematological malignancy in which no prior predisposing syndrome was reported. In this circumstance, so-called pure familial leukemia, lymphoma, or myeloma, the intergenerational incidence of disease occurred in ostensibly healthy persons. These families have been grouped into sets in which (a) anticipation, (b) immune abnormalities, (c) linkage to HLA phenotypes, (d) linkage to chromosome abnormalities, or (e) gene abnormalities have been reported.

read more | 3078 reads

Getting the Facts on Lymphoma vaccines - Lymphoma Research Foundation
By admin at 2006-11-22 10:51

Getting a vaccine "shot" is the best way to prevent infections like tetanus, polio, and measles. These vaccine shots stimulate your immune system (antibodies and T cells) to fight off the germs that cause these diseases.


New kinds of experimental vaccines are now being studied as treatments for non-Hodgkin's lymphomaterm (NHL). These vaccines are not designed to prevent lymphoma, but rather treat it once it has arisen, and are thus termed "therapeutic vaccines." As with other types of so-called immunotherapy (e.g., therapeutic monoclonal antibodies), lymphoma vaccines are designed to work by harnessing the power of a patient's own immune system to fight off his or her tumor.

read more | 1 comment | 2064 reads

Syndicate content

sponsored links



Subscribe to our newsletter to receive info on our site or upcoming clinical trials

Confirm your email address

HTML format

Please select the newsletters you want to sign up to:

  • Cancerfocus
    Receive updates from Cancerfocus.
  • Breast
  • Colon
  • Kidney
  • Leukemia
  • Liver
  • Lung
  • Melanoma
  • Mesothelioma
  • Myeloma
  • Neck
  • Pancreatic
  • Prostate

Syndicate content

All times are GMT -5. The time now is 05:01 PM.